top of page

Bristol Myers Follows Pfizer into Cancer Care.

Updated: Jan 6


Well, folks, it seems like the pharmaceutical giants are on a shopping spree, and this time, it's Bristol Myers Squibb making headlines with their $4.1 billion acquisition of RayzeBio. Now, you might be wondering, how does this connect to the Pfizer-Seagen saga I delved into earlier? Hold onto your hats, because there might be more to this acquisition than meets the eye.


RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company, has been making waves in the world of cancer treatment. They're working on several cancer treatments that target solid tumors, including some tricky ones like gastroenteropancreatic neuroendocrine tumors (GEP-NETs), small cell lung cancer, and hepatocellular carcinoma. Sounds impressive, right? But here's the kicker – they're into delivering radioactive payloads to cancer cells in a targeted manner. Now, where have we heard about targeting cancer cells before? Ah, yes, Pfizer's venture into Turbo Cancers.


What's truly eyebrow-raising is the share price situation. RayzeBio's shares were hovering just above $30 when Bristol Myers Squibb swooped in with an offer of $62.50 per share. That's more than double the market price! Now, why would Bristol Myers Squibb be willing to overpay by such a significant margin if they didn't see something big on the horizon? It's as if they know this is a golden opportunity, much like Pfizer's extravagant $43 billion spending spree.


Bristol Myers Squibb CEO Christopher Boerner seems pretty thrilled about this acquisition. He's talking about enhancing their oncology portfolio and strengthening growth opportunities. But here's the intriguing part – he mentions that radiopharmaceutical therapeutics are already transforming cancer care, and RayzeBio is pioneering this novel modality. It's almost as if they're following in Pfizer's footsteps but taking it up a notch.


And let's not forget about the manufacturing facility in Indianapolis that Bristol Myers Squibb is acquiring. It's expected to start GMP drug production in the first half of 2024. Now, why would a pharmaceutical company need to invest in manufacturing facilities if they weren't planning something big? It's like they're gearing up for a massive production scale, just like we heard with Pfizer.



RayzeBio's CEO and President, Ken Song, is singing praises about this acquisition. He calls Bristol Myers Squibb the ideal partner, citing their expertise in developing, commercializing, and manufacturing treatments on a global scale. But what's the real motive here? Are they getting ready for a radiopharmaceutical revolution, just as Pfizer is diving into the world of cancer treatment "AT SCALE"?


My dear readers, the plot thickens, rumours are also swirling that Astrazeneca has a bid in for Gracell yet another Cancer specialist. Alone they may not mean much but put this all together and the connections between these pharmaceutical giants are becoming clearer.


We're witnessing a shift in the industry, a move towards treating cancers caused by mRNA vaccines and a fascination with radiopharmaceutical therapeutics. Why are all the pharmaceutical giants investing into cancer? Is there something they're not telling us? Stay cheeky, my friends, and keep questioning the narrative


Thats Just what I think though, in the meantime:


Trust No Single Source

Trust Your Gut &

Stay Curious


Sally Joe


For media inquiries, please contact:


UK - 020 3404 2295

USA - 0650 278 4440

AUS - 02 9072 9499


Help Support Sally Joe and the rest of our Authors by visiting the store to get your copy of the latest Anonymous Author Novel, or some cool merch.


5 views0 comments

Comments


bottom of page